• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Gout Drug Shows Promise in Two Pivotal Trials

Gout Drug Shows Promise in Two Pivotal Trials

January 4, 2008
CenterWatch Staff

Savient Pharmaceuticals reported positive results from two phase III trials, GOUT 1 [Gout Outcomes and Uric acid Treatment] and GOUT 2, of Puricase, a pegylated recombinant urate oxidase for the treatment of gout. The disease is caused by the deposit of urate crystals (via uric acid) in the body's tissues such as joints, tendons and organs. Most traditional treatments have centered on blocking the production of uric acid in the body, whereas Puricase attempts to reduce the levels of uric acid in the blood stream.

Puricase (8 mg) administered by a two hour intravenous infusion every two weeks or every four weeks met the primary efficacy endpoint in the intent-to-treat (ITT) and per protocol analyses.

The primary endpoint was normalization of plasma uric acid during months 3 and 6 of the clinical trials. In the ITT analysis the mean responder rate for the every two-week dose group pooled across both studies was 42% (p is less than 0.001) and the mean responder rate for the every four-week dose group was 35% (p is less than 0.001).

In the per protocol analysis the responder rate for the every two weeks dose group was 61% (p is less than 0.001), and every four weeks was 50% (p is less than 0.001). The placebo responder rate for placebo was zero in both the ITT and Per Protocol analyses. A key secondary endpoint was reduction of gout tophi (grouped crystal deposits).

The every two week dose arm attained statistical significance in the pre-specified pooled analysis (p equal to 0.005) for the elimination of gout tophi. The every four week dose group did not attain statistical significance. Treatment was generally well tolerated.

Based on these results, Savient plans to file a (Biologic Li cease Application) BLA with the U.S. Food and Drug Administration (FDA) in 2008. Puricase was licensed from Duke University in 1998. According to the Centers for Disease Control (CDC), Gout may affect as much as 2.7% of the U.S. population alone.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing